Dr. Steven D. Nathan, MD, FCCP, is the medical
director of Inova’s Advanced Lung Disease Program and Lung Transplant Program.
He is also a professor of medicine at the University of Virginia. Dr. Nathan is
board certified in pulmonary diseases, critical care medicine and internal
medicine. The author of more than 500 publications, Dr. Nathan is
internationally recognized for his expertise in advanced lung diseases. He is
co-editor of two books on idiopathic pulmonary fibrosis that provide
pulmonologists and other healthcare workers with an up-to-date review of the
background and advances in the field Idiopathic Pulmonary Fibrosis and Guide to
Clinical Management of Idiopathic Pulmonary Fibrosis. He also has written
original research manuscripts, abstracts, reviews and book chapters. Dr. Nathan
is a reviewer for multiple journals and is on the editorial board for the
journal, Thorax. He has served on multiple committees, including U.S. Food and
Drug Administration advisory boards as well as steering committees for clinical
trials in IPF and pulmonary hypertension, where he has also served as chair. Dr.
Nathan is a member of several professional medical associations, including the
American Thoracic Society, the American College of Chest Physicians, and the
International Society for Heart and Lung Transplantation. He has delivered
talks and been chairperson of numerous sessions at many national and
international conferences.
Dr. Steven D. Nathan, MD, FCCP, is the medical
director of Inova’s Advanced Lung Disease Program and Lung Transplant Program.
He is also a professor of medicine at the University of Virginia. Dr. Nathan is
board certified in pulmonary diseases, critical care medicine and internal
medicine. The author of more than 500 publications, Dr. Nathan is
internationally recognized for his expertise in advanced lung diseases. He is
co-editor of two books on idiopathic pulmonary fibrosis that provide
pulmonologists and other healthcare workers with an up-to-date review of the
background and advances in the field Idiopathic Pulmonary Fibrosis and Guide to
Clinical Management of Idiopathic Pulmonary Fibrosis. He also has written
original research manuscripts, abstracts, reviews and book chapters. Dr. Nathan
is a reviewer for multiple journals and is on the editorial board for the
journal, Thorax. He has served on multiple committees, including U.S. Food and
Drug Administration advisory boards as well as steering committees for clinical
trials in IPF and pulmonary hypertension, where he has also served as chair. Dr.
Nathan is a member of several professional medical associations, including the
American Thoracic Society, the American College of Chest Physicians, and the
International Society for Heart and Lung Transplantation. He has delivered
talks and been chairperson of numerous sessions at many national and
international conferences.